Aug 22, 2017   SOURCE: PR NewsWire

The Gastroesophageal Cancer Market is Expected to Grow Sevenfold Over the Next Ten Years Capturing $13 Billion in 2026

BURLINGTON, Mass., Aug. 22, 2017 /PRNewswire/ -- Decision Resources Group finds that the gastroesophageal cancer market will grow significantly from almost $2 billion in 2016 to $13 billion in 2026, making it one of the fastest growing oncology indications. Fueling this robust growth will be the approval of multiple novel premium-priced biologics, namely PD-1/PD-L1 inhibitors.

Learn more about the full report here: http://bit.ly/2x5x3sq

Other key findings from the Disease Landscape & Forecast report entitled Gastroesophageal Cancer:

    --  Gastric cancer vs. esophageal cancer: The gastric and GEJ adenocarcinoma
        market will account for three-quarters of the total gastroesophageal
        market in 2026. This is largely attributable to the high incidence of
        gastric and GEJ adenocarcinoma in Japan.
    --  Growth of the market in Japan: Gastroesophageal cancer sales in Japan
        will increase from $1 billion in 2016 to over $6 billion in 2026; this
        region will account for half of total sales in 2026.
    --  New market entrants for first-line HER2-negative gastric and GEJ
        adenocarcinoma: By 2026, this will become a dynamic space with multiple
        agents jostling for patient share; Bristol-Myers Squibb/Ono
        Pharmaceutical's Opdivo with or without Yervoy , Merck & Co.'s Keytruda
        (pembrolizumab), Merck KGaA/Pfizer's Bavencio and Gilead Science's
        matrix metalloproteinase-9 inhibitor, andecaliximab.
    --  Immune checkpoint inhibitors will drive sales in gastroesophageal
        cancer: The emergence of immune checkpoint inhibitors, particularly PD-1
        inhibitors (i.e., Opdivo and Keytruda) during the first half of our
        forecast period, will drive considerable growth in sales through 2026.
        This is compounded by the expected approval of Bavencio as the only
        first-line maintenance treatment for gastric and GEJ adenocarcinoma.

Comments from Decision Resources Group Analyst Paul Wilcock Ph.D.:

    --  "This is an exciting time in esophageal cancer, with the expected
        approval of Keytruda as a second-line treatment in 2019--the first
        noncytotoxic agent to be approved in this indication. Hopefully this
        will pave the way for multiple label expansions for Keytruda, as well as
        the approval of Opdivo with or without Yervoy or chemotherapy. The
        outlook for esophageal cancer patients is likely to significantly
        improve over the forecast period."
    --  "Despite the expected approval of more efficacious, better-tolerated
        agents across many of the gastroesophageal cancer populations over the
        forecast period, we expect some unmet needs will persist. For example,
        the urgent need for a selection of more efficacious drug treatment
        options for resectable disease, and the need for a range of drug classes
        aside from PD-1/CTLA-4 inhibitors and cytotoxic agents in esophageal
        cancer will likely remain in 2026."

About Decision Resources Group
DRG, a subsidiary of Piramal Enterprises Ltd., is the premier source for global healthcare data and market intelligence. A trusted partner for over 20 years, DRG helps companies competing in the global healthcare industry make informed business decisions. Organizations committed to the developing and delivering life-changing therapies to patients rely on DRG's in-house team of expert healthcare analysts, data scientists, and consultants for critical guidance. DRG products and services, built on extensive data assets and delivered by experts, empower organizations to succeed in complex healthcare markets.

Media contact:

Decision Resources Group
Whitney Goldstein
617-747-9037
wgoldstein@dresources.com

View original content with multimedia:http://www.prnewswire.com/news-releases/the-gastroesophageal-cancer-market-is-expected-to-grow-sevenfold-over-the-next-ten-years-capturing-13-billion-in-2026-300507639.html

SOURCE Decision Resources Group